Immunic IMUX
NASDAQ IMUX
$8.12 +0.08 (+1.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Immunic (IMUX) Restructuring Costs (2018 - 2019)

Updated

Immunic's Restructuring Costs came in at $6.37 million for Q1 2019.

Analysis

Immunic (IMUX) Restructuring Costs (2018 - 2019) Analysis & Trends

Over the trailing twelve months to Mar 31, 2019, Immunic reported Restructuring Costs of $8.76 million; for FY2018, it was $2.4 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Immunic 341.81 Mn -50.53 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 6.37 Mn
Sep 30, 2018 2.40 Mn
API Access

Immunic Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=IMUX&period=max&api_key=YOUR_API_KEY